Tags

Type your tag names separated by a space and hit enter

Intermittent Fugu parathyroid hormone 1 (1-34) is an anabolic bone agent in young male rats and osteopenic ovariectomized rats.
Bone. 2008 Jun; 42(6):1164-74.BONE

Abstract

Human parathyroid hormone (hPTH) is currently the only treatment for osteoporosis that forms new bone. Previously we described a fish equivalent, Fugu parathyroid hormone 1 (fPth1) which has hPTH-like biological activity in vitro despite fPth1(1-34) sharing only 53% identity with hPTH(1-34). Here we demonstrate the in vivo actions of fPth1(1-34) on bone. In study 1, young male rats were injected intermittently for 30 days with fPth1 [30 microg-1,000 microg/kg body weight (b.w.), (30fPth1-1,000fPth1)] or hPTH [30 microg-100 microg/kg b.w. (30hPTH-100hPTH)]. In proximal tibiae at low doses, the fPth1 was positively correlated with trabecular bone volume/total volume (TbBV/TV) while hPTH increased TbBV/TV, trabecular thickness (TbTh) and trabecular number (TbN). 500fPth1 and 1000fPth1 increased TbBV/TV, TbTh, TbN, mineral apposition rate (MAR) and bone formation rate/bone surface (BFR/BS) with a concomitant decrease in osteoclast surface and number. In study 2 ovariectomized (OVX), osteopenic rats and sham operated (SHAM) rats were injected intermittently with 500 microg/kg b.w. of fPth1 (500fPth1) for 11 weeks. 500fPth1 treatment resulted in increased TbBV/TV (151%) and TbTh (96%) in the proximal tibiae due to increased bone formation as assessed by BFR/BS (490%) and MAR (131%). The effect was restoration of TbBV/TV to SHAM levels without any effect on bone resorption. 500fPth1 also increased TbBV/TV and TbTh in the vertebrae (L6) and cortical thickness in the mid-femora increasing bone strength at these sites. fPth1 was similarly effective in SHAM rats. Notwithstanding the low amino acid sequence homology with hPTH (1-34), we have clearly established the efficacy of fPth1 (1-34) as an anabolic bone agent.

Authors+Show Affiliations

Department of Medicine, University of Melbourne, Austin Health, Studley Road, Heidelberg, VIC, Australia. mcmanusj@unimelb.edu.auNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18387351

Citation

McManus, Julie F., et al. "Intermittent Fugu Parathyroid Hormone 1 (1-34) Is an Anabolic Bone Agent in Young Male Rats and Osteopenic Ovariectomized Rats." Bone, vol. 42, no. 6, 2008, pp. 1164-74.
McManus JF, Davey RA, Maclean HE, et al. Intermittent Fugu parathyroid hormone 1 (1-34) is an anabolic bone agent in young male rats and osteopenic ovariectomized rats. Bone. 2008;42(6):1164-74.
McManus, J. F., Davey, R. A., Maclean, H. E., Doust, E. A., Chiu, W. S., Sims, N. A., Bouxsein, M. L., Glatt, V., Zajac, J. D., & Danks, J. A. (2008). Intermittent Fugu parathyroid hormone 1 (1-34) is an anabolic bone agent in young male rats and osteopenic ovariectomized rats. Bone, 42(6), 1164-74. https://doi.org/10.1016/j.bone.2008.01.015
McManus JF, et al. Intermittent Fugu Parathyroid Hormone 1 (1-34) Is an Anabolic Bone Agent in Young Male Rats and Osteopenic Ovariectomized Rats. Bone. 2008;42(6):1164-74. PubMed PMID: 18387351.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Intermittent Fugu parathyroid hormone 1 (1-34) is an anabolic bone agent in young male rats and osteopenic ovariectomized rats. AU - McManus,Julie F, AU - Davey,Rachel A, AU - Maclean,Helen E, AU - Doust,Elizabeth A, AU - Chiu,W S Maria, AU - Sims,Natalie A, AU - Bouxsein,Mary L, AU - Glatt,Vaida, AU - Zajac,Jeffrey D, AU - Danks,Janine A, Y1 - 2008/02/13/ PY - 2007/10/19/received PY - 2007/12/21/revised PY - 2008/01/25/accepted PY - 2008/4/5/pubmed PY - 2008/10/1/medline PY - 2008/4/5/entrez SP - 1164 EP - 74 JF - Bone JO - Bone VL - 42 IS - 6 N2 - Human parathyroid hormone (hPTH) is currently the only treatment for osteoporosis that forms new bone. Previously we described a fish equivalent, Fugu parathyroid hormone 1 (fPth1) which has hPTH-like biological activity in vitro despite fPth1(1-34) sharing only 53% identity with hPTH(1-34). Here we demonstrate the in vivo actions of fPth1(1-34) on bone. In study 1, young male rats were injected intermittently for 30 days with fPth1 [30 microg-1,000 microg/kg body weight (b.w.), (30fPth1-1,000fPth1)] or hPTH [30 microg-100 microg/kg b.w. (30hPTH-100hPTH)]. In proximal tibiae at low doses, the fPth1 was positively correlated with trabecular bone volume/total volume (TbBV/TV) while hPTH increased TbBV/TV, trabecular thickness (TbTh) and trabecular number (TbN). 500fPth1 and 1000fPth1 increased TbBV/TV, TbTh, TbN, mineral apposition rate (MAR) and bone formation rate/bone surface (BFR/BS) with a concomitant decrease in osteoclast surface and number. In study 2 ovariectomized (OVX), osteopenic rats and sham operated (SHAM) rats were injected intermittently with 500 microg/kg b.w. of fPth1 (500fPth1) for 11 weeks. 500fPth1 treatment resulted in increased TbBV/TV (151%) and TbTh (96%) in the proximal tibiae due to increased bone formation as assessed by BFR/BS (490%) and MAR (131%). The effect was restoration of TbBV/TV to SHAM levels without any effect on bone resorption. 500fPth1 also increased TbBV/TV and TbTh in the vertebrae (L6) and cortical thickness in the mid-femora increasing bone strength at these sites. fPth1 was similarly effective in SHAM rats. Notwithstanding the low amino acid sequence homology with hPTH (1-34), we have clearly established the efficacy of fPth1 (1-34) as an anabolic bone agent. SN - 8756-3282 UR - https://www.unboundmedicine.com/medline/citation/18387351/Intermittent_Fugu_parathyroid_hormone_1__1_34__is_an_anabolic_bone_agent_in_young_male_rats_and_osteopenic_ovariectomized_rats_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S8756-3282(08)00076-8 DB - PRIME DP - Unbound Medicine ER -